CERo Therapeutics Holdings, Inc., (NASDAQ: CERO) shares were unchanged Wednesday. The company, an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced an agreement with the University of California Davis for the manufacturing of CER-1236 to be used in the Company's upcoming Phase 1 clinical trial for Acute Myeloid Leukemia (AML). The Company believes it is on track for dosing the first patient in the first half of 2025.

CEO Chris Ehrlich commented, "The precision and compliance in manufacturing is critical to successful development and execution of clinical trials and UC Davis is a leading institution with an impeccable reputation in this area. The manufacturing of product is among the final steps necessary to have completed prior to patient dosing, and we are looking forward to continuing to drive the process forward."

CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERO shares retreated 0.06 cents to 90 cents.

COMTEX_463754083/2559/2025-03-19T10:12:41